The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
For decades, HER2-positive breast cancer was associated with poor outcomes and higher mortality rates than other breast cancer subtypes. However, the advent of Trastuzumab (Herceptin) has significantly changed the treatment paradigm of patients afflicted with HER2-positive breast cancer. The discove...
Main Authors: | Aena Patel, Nisha Unni, Yan Peng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/8/2081 |
Similar Items
-
Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC
by: Chen, J., et al.
Published: (2022) -
Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials)
by: I V Kolyadina, et al.
Published: (2014-12-01) -
Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)
by: Benjamin Daniels, et al.
Published: (2019-09-01) -
Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
by: Helena Earl, et al.
Published: (2020-08-01) -
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)